Historically, RSV has been studied mainly in infants and older adults, but recent research shows that it also poses a ...

Hospitalization rates from respiratory syncytial virus (RSV) infection rose with age. Also, hospitalizations were more likely among nursing home residents and older adults with other health issues, ...

Among older adults in Spain, hospitalization rates from respiratory syncytial virus (RSV) infection increases progressively ...

A new study published in the Journal of American Medical Association showed that nirsevimab offers protection against a ...

On 12 March 2025, the World Health Organization (WHO) prequalified the first maternal respiratory syncytial virus (RSV) vaccine to protect infants ...

A study from Yale University today in JAMA Network Open reveals substantial protection by the preventive drug nirsevimab ...

After months of rapid respiratory disease spread and sickness, Georgia and Atlanta cases of COVID-19, flu, or RSV appear to be declining from their respective winter peaks.

RSV leads to approximately 1.4 million hospitalizations and over 13,000 in-hospital deaths worldwide among infants under six ...

From next Monday, 17 March, free immunisation from respiratory syncytial virus (RSV) will be available to all newborn babies.